Trials / Completed
CompletedNCT00083694
Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
UARK, 98-032, Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (planned)
- Sponsor
- University of Arkansas · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.
Detailed description
Patients will take Thalidomide tablets at bedtime daily until remission. The dose will be increased gradually and modified according to side-effects. The drug will be given daily up to the time of complete remission then as long as it is beneficial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thalidomide |
Timeline
- Start date
- 1998-08-01
- Completion
- 2005-05-01
- First posted
- 2004-05-31
- Last updated
- 2010-07-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00083694. Inclusion in this directory is not an endorsement.